Electroacupuncture plus immunotherapy after surgery for early non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a large, multicenter, randomized Phase 2/3 parallel-controlled study comparing immune checkpoint inhibitor (ICI) therapy alone versus ICI combined with electroacupuncture or ICI combined with Zilongjin tablet in patients after curative surgery for stage II–III non‑small cell lung cancer. Eligible participants are adults without actionable driver mutations who have completed 1–4 cycles of postoperative adjuvant chemotherapy and meet traditional Chinese medicine syndrome criteria. The trial will collect safety data and clinical outcomes including recurrence, metastasis, survival, and quality of life measures to determine whether the added therapies improve long-term outcomes. The protocol follows evidence-based standards and aims to produce high-quality randomized data on the effectiveness and safety of combining electroacupuncture and Zilongjin tablet with modern immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Non-tumor patients with stage Ⅱ, ⅢA, ⅢB (N2) non-small cell lung cancer diagnosed by pathology or cytology after surgery; (2) driver mutations negative patients; (3) Postoperative adjuvant chemotherapy was received for 1 to 4 cycles;(4)conforms to two qi syndrome of traditional Chinese medicine syndrome differentiation diagnosis of patients; (5) aged 18 to 80 years old; (6) expected lifetime \> 6 months; (7) ECOG 0 to 2 points; (8) patients willing to accept this solution treatment, adherence to the good.

Exclusion Criteria:

* (1) Patients with other malignant tumors in the past or at the same time within 5 years; (2) has a serious heart, liver and kidney damage, or other serious complications; (3) the R1, R2, need after resection, postoperative adjuvant radiotherapy patients; (4) with mental disorders; (5) has a variety of drug allergy, allergic constitution; (6) in pregnancy or lactation women.

Where it's running

• First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Fanming Kong Director of Oncology Department, PhD
• Email: kongfanming08@163.com
• Phone: + 86 22 27986525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Electroacupuncture plus PD‑1 immunotherapy for advanced non‑small cell lung cancer with ECOG 2

  This trial will see if adding electroacupuncture to PD‑1 immunotherapy helps people with advanced non‑small cell lung cancer who have an ECOG performance status of 2.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07239661

• Electroacupuncture plus PD-1 immunotherapy for older adults with advanced non-small cell lung cancer

  It will test whether adding electroacupuncture to PD‑1 immunotherapy helps people aged 65 and older with advanced non‑small cell lung cancer live longer, feel better, or have fewer side effects.

  Recruiting First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Tianjin, Tianjin Municipality · NCT07086300

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.